TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03474081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match FF/UMEC/VI
Description: Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match tiotropium
Description: Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA inhaler
Description: ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA inhaler
Description: ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANDIHALER
Description: Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANDIHALER
Description: Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
Study: NCT02077361

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: rAAV2.REP1 vector
Description: No additional details needed.
Study: NCT03002701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UNDERPIN-ICU program
Description: UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
Study: NCT03591497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: As described in Experimental arm description.
Study: NCT00920790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
Study: NCT01736969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RD047-023
Description: Experimental hydrogel

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predicate Device
Study: NCT04166565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
Study: NCT03855800

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood, stool, pancreatic juice and cyst fluid collection
Description: Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
Study: NCT04166565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
Study: NCT03458182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Added exercise
Description: After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
Study: NCT03928067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNF + SAF
Description: Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
Study: NCT03399825

Intervention type: DEVICE
Intervention: OCT-A
Description: optical coherence tomography angiography~Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: OCT-A
Description: optical coherence tomography angiography~Imaging with optical coherence tomography angiography

Intervention type: DEVICE
Intervention: OCT-A
Description: optical coherence tomography angiography~Imaging with optical coherence tomography angiography
Study: NCT04031755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
Study: NCT02194699

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT01063114

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam radiation
Description: Given once a day, 5 days a week (Monday-Friday)
Study: NCT02029885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Therapy (Surround Sound)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Study: NCT02245295

Intervention type: PROCEDURE
Intervention: Moderate Sedation for EBUS/TBNA
Description: EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).

Intervention type: PROCEDURE
Intervention: General anesthesia for EBUS/TBNA
Description: EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
Study: NCT04031755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
Study: NCT02813681

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US-epidural SVD
Description: participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: US sham- epidural SVD
Description: participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spontaneous vaginal delivery without an Epidural
Description: Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
Study: NCT02879864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light therapy
Description: The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
Study: NCT02500706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
Study: NCT02872493

Intervention type: PROCEDURE
Intervention: Small bowel length measurement
Description: The total length of the small bowel with be measured at the time of the bariatric surgical operation.
Study: NCT03855800

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood, stool, pancreatic juice and cyst fluid collection
Description: Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
Study: NCT01729806

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04700891

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Olfactory identification test
Description: Burghart Sniffin' Sticks Screening 12 Test Olfactory function will be evaluated through the Sniffin' Sticks test which is a validated psychophysical testing method. Sniffin' Sticks test is based on pen-like odor dispensing devices that will be presented to the patients. The short version of this test will be used and will consist solely of a test of odor identification function.
Study: NCT00760734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low pressure hyperbaric oxygen therapy
Description: HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low pressure hyperbaric oxygen therapy
Description: HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low pressure hyperbaric oxygen therapy
Description: HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low pressure hyperbaric oxygen therapy
Description: HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
Study: NCT03765788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg, s.c.
Description: Secukinumab 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone was provided as tablets (1 mg, 5 mg, 10 mg, 20 mg tablets) for daily administration as tapered regimen from a dose of 25 mg to 60 mg at Baseline to 1 mg at Week 26 (last dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300 mg was administered by subcutaneous (s.c.) injections using 1 mL pre-filled syringes (PFSs) throughout the study.
Study: NCT01590303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
Study: NCT03436056

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
Description: Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)
Description: Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose
Description: Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
Study: NCT00125515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: One arm receives 30 mg bid and the other arm receives receives 15mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: One arm receives 30 mg bid and the other arm receives receives 15mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
Study: NCT03495921

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vigil
Description: Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Injectable formulation of irinotecan was distributed from central supplier. 1 Cycle (5 doses of 50 mg/m2 per syringe) was drawn into provided oral syringes and dispenses to the subject with instructions to refrigerate until administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Dose: 100 mg/m2 daily, oral Schedule: Days 1-5, every 21 days Administered at least 1 hour before Irinotecan.
Study: NCT03855800

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pancreatic Surgery
Description: Surgical resection of pancreatic cyst

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy Exam
Description: Clinically indicated endoscopic ultrasound
Study: NCT01274611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction-Curettage
Description: The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
Study: NCT00846716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone add on to SU or biguanide
Description: As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SU or Biguanide
Description: As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.